Patents Assigned to Genomictree, Inc.
-
Patent number: 11268155Abstract: The present disclosure relates to a method for detecting CpG methylation of SDC2 (Syndecan 2) gene, a kit for detecting CpG methylation of SDC2 (Syndecan 2) gene, and a method for detecting CpG methylation of SDC2 (Syndecan 2) gene for a colorectal cancer diagnosis.Type: GrantFiled: August 16, 2019Date of Patent: March 8, 2022Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 11186866Abstract: The present disclosure relates to a method of detecting methylation of target DNA in a multiplex manner and a composition for detecting methylation of target DNA, and more particularly to a method for detecting methylation of target DNA, comprising: constructing an oligonucleotide, which comprises a target-specific sequence capable of binding complementarily to the target DNA and a universal primer that does not bind complementarily to the target DNA; linearly amplifying the target DNA for linear target enrichment by using the oligonucleotide as a primer; and amplifying the linearly amplified target DNA using an oligonucleotide, which is capable of binding complementarily to the linearly amplified target DNA, a universal primer, and a probe.Type: GrantFiled: September 29, 2017Date of Patent: November 30, 2021Assignee: GENOMICTREE, INC.Inventors: Sungwhan An, TaeJeong Oh
-
Patent number: 10767231Abstract: The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5?UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression.Type: GrantFiled: November 15, 2017Date of Patent: September 8, 2020Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 10428390Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: GrantFiled: September 20, 2017Date of Patent: October 1, 2019Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 10428389Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: GrantFiled: July 27, 2017Date of Patent: October 1, 2019Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 10428388Abstract: The present disclosure relates to a method for detecting CpG methylation of SDC2 (Syndecan 2) gene, a kit for detecting CpG methylation of SDC2 (Syndecan 2) gene, and a method for detecting CpG methylation of SDC2 (Syndecan 2) gene for a colorectal cancer diagnosis.Type: GrantFiled: July 25, 2017Date of Patent: October 1, 2019Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh, Hyun Cheol Chung
-
Patent number: 10266900Abstract: The present invention relates to the novel use of syndecan-2 (SDC2) gene as a CpG methylation biomarker for detecting precancerous lesions, and more particularly, to the use of the SDC2 gene as a biomarker to early diagnose colorectal precancerous lesions by measuring the degree of methylation of the SDC2 gene. The present invention provides a method of providing information for diagnosis of precancerous lesions by detecting methylation of the CpG islands of the SDC2 gene. In addition, the use of the methylation detection and kit according to the present invention makes it possible to diagnose colorectal precancerous lesions at an early transformation stage, thus enabling the early diagnosis of colorectal precancerous lesions. Furthermore, the methylation detection method and kit of the present invention enables colorectal precancerous lesions to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.Type: GrantFiled: August 14, 2014Date of Patent: April 23, 2019Assignee: GENOMICTREE, INC.Inventors: Sungwhan An, Tae Jeong Oh
-
Patent number: 10113203Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: September 19, 2017Date of Patent: October 30, 2018Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 10023908Abstract: A method is described for detecting a target nucleic acid, in which the target nucleic acid is amplified in the presence of a proofreading DNA polymerase and an allele-specific reactive primer (ASRP) including (i) a nucleotide sequence complementary to the target nucleic acid and (ii) modified nucleotide(s) located in a region from a nucleotide located right before a non-complementary nucleotide on the 5?-side of the non-complementary nucleotide, so that an amplification product of the target nucleic acid is produced when the ASRP is complementary to the target nucleic acid, and so that when the ASRP is not complementary to the target nucleic acid, an amplification product of the target nucleic acid will not be produced. The detection method has a very high specificity of amplification, and is useful for applications such as detecting mutations, detecting methylation of CpG after bisulfite treatment, and detecting target DNA from a DNA library.Type: GrantFiled: April 16, 2013Date of Patent: July 17, 2018Assignee: Genomictree, Inc.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 9850540Abstract: The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5?UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression.Type: GrantFiled: February 18, 2009Date of Patent: December 26, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Publication number: 20170335407Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: ApplicationFiled: July 27, 2017Publication date: November 23, 2017Applicant: GENOMICTREE, Inc.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 9797017Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: May 3, 2017Date of Patent: October 24, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 9783857Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: May 3, 2017Date of Patent: October 10, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 9752197Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.Type: GrantFiled: January 29, 2016Date of Patent: September 5, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Tae Jeong Oh
-
Patent number: 9745622Abstract: The present invention relates to a method for detecting the methylation of colorectal cancer-specific marker genes for colorectal cancer diagnosis, and more particularly to a method of detecting colorectal cancer-specific marker genes, which are methylated specifically in colorectal cancer cells, to provide information for diagnosing colorectal cancer. The use of the inventive method for detecting methylation and the inventive composition, kit and nucleic chip for diagnosing colorectal cancer makes it possible to diagnose colorectal cancer at an early transformation stage, thus enabling the early diagnosis of colorectal cancer. In addition, the inventive method enables colorectal cancer to be effectively diagnosed in an accurate and rapid manner compared to conventional methods.Type: GrantFiled: October 14, 2010Date of Patent: August 29, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh, Hyun Cheol Chung
-
Publication number: 20170240976Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: ApplicationFiled: May 3, 2017Publication date: August 24, 2017Applicant: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho MOON, Tae Jeong Oh
-
Publication number: 20170240977Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: ApplicationFiled: May 3, 2017Publication date: August 24, 2017Applicant: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho MOON, Tae Jeong Oh
-
Patent number: 9695473Abstract: The present invention relates to a genotyping method, and more particularly to an ID sequence, which is assigned to each genotype, and a multiplex genotyping method which uses the ID sequence. When pyrosequencing is performed using the ID sequence, a unique and simple pyrogram can be obtained for each genotype. Thus, the use of the ID sequence makes it possible to genotype viral genes, disease genes, bacterial genes and identification genes in a simple and efficient manner. In addition, a genotyping primer of the invention can be used in various genotyping methods which are performed using dispensation orders and sequencing methods.Type: GrantFiled: July 28, 2015Date of Patent: July 4, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Myung Sok Oh
-
Patent number: 9670551Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: February 5, 2016Date of Patent: June 6, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 9670552Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: February 5, 2016Date of Patent: June 6, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh